<DOC>
	<DOCNO>NCT02944396</DOCNO>
	<brief_summary>This study seek establish recommended Phase 2 dose ( RPTD ) veliparib combination nivolumab platinum doublet chemotherapy ( carboplatin/paclitaxel carboplatin/pemetrexed ) ( Phase 1 portion ) ass whether addition nivolumab veliparib combination platinum doublet chemotherapy result improve progression free survival ( PFS ) compare veliparib platinum doublet chemotherapy alone participant metastatic advance Non-small Cell Lung Cancer ( NSCLC ) ( Phase 2 portion ) .</brief_summary>
	<brief_title>Study Veliparib Combination With Nivolumab Platinum Doublet Chemotherapy Participants With Metastatic Advanced Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participant must life expectancy great 12 week , Participant must cytologically histologically confirm Nonsmall Cell Lung Cancer ( NSCLC ) . Participant must metastatic advanced NSCLC ( Stage IIIB IV ) amenable surgical resection radiation chemoradiation curative intent time study screen . Participant must least 1 unidimensional measurable NSCLC lesion compute tomography ( CT ) scan define Response Evaluation Criteria Solid Tumors ( RECIST ) ( version 1.1 ) . Participant must resolution Grade 1 low toxic effect ( except alopecia ) recent therapy prior Cycle 1 Day 2 . Participant must Eastern Cooperative Oncology Group ( ECOG ) Performance Score 0 1 . Participant must adequate bone marrow , renal , hepatic function . Participant receive prior cytotoxic chemotherapy ( include chemotherapy combination radiotherapy ) NSCLC , except adjuvant neoadjuvant therapy accompany surgery curative intent complete one year prior Cycle 1 Day 2 . Participant receive prior therapy Poly ( ADPribose ) Polymerase ( PARP ) inhibitor . Participant receive prior treatment antiprogrammed cell death protein1 ( antiPD1 ) , PD Ligand1 ( PDL1 ) PD Ligand2 ( PDL2 ) agent antibody target immunoregulatory receptor mechanisms . Participant receive radiation therapy lung great 30 Gy within 6 month , antineoplastic biologic therapy within 21 day , major surgery within 21 day , tyrosine kinase inhibitor therapy within 7 day , palliative radiation within 7 day first dose study medication . Participant untreated central nervous system ( CNS ) metastases .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Common Terminology Criteria Adverse Events ( CTCAE )</keyword>
	<keyword>Immuno Oncology</keyword>
	<keyword>veliparib</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>Poly ( ADP ) ribose polymerase ( PARP )</keyword>
	<keyword>Platinum Doublet Chemotherapy</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>nivolumab</keyword>
	<keyword>metastatic</keyword>
	<keyword>Response Evaluation Criteria In Solid Tumors ( RECIST )</keyword>
	<keyword>pemetrexed</keyword>
	<keyword>Eastern Cooperative Oncology Group ( ECOG )</keyword>
	<keyword>carboplatin</keyword>
</DOC>